1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2022 report [Internet]. Fontana: Global Initiative for Chronic Obstructive Lung Disease; 2021 [cited 2021 Dec 19]. Available from:
https://goldcopd.org.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789-858.
3. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-88.
7. Montuschi P, Malerba M, Santini G, Miravitlles M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today 2014;19:1928-35.
8. Agusti A. The path to personalised medicine in COPD. Thorax 2014;69:857-64.
9. Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013;41:1252-6.
11. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
13. Kim WD, Chi HS, Choe KH, Oh YM, Lee SD, Kim KR, et al. A possible role for CD8 + and non-CD8 + cell granzyme B in early small airway wall remodelling in centrilobular emphysema. Respirology 2013;18:688-96.
14. Thurlbeck WM, Wright JL. Emphysema: classification, morphology, and associations. In: Thurlbeck WM, Wright JL, editors. Thurlbeck’s chronic airflow obstruction. 2nd ed. Hamilton: B.C. Decker Inc; 1999. p. 85-137.
16. Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities. Am Rev Respir Dis 1991;144:1385-90.
17. Kim WD, Ling SH, Coxson HO, English JC, Yee J, Levy RD, et al. The association between small airway obstruction and emphysema phenotypes in COPD. Chest 2007;131:1372-8.
20. Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:233-9.
23. Thurlbeck WM, Wright JL. Chapter 5. Emphysema: etiology, pathogenesis, animal models, and epidemiology. In: Thurlbeck WM, Wright JL, editors. Thurlbeck’s chronic airflow obstruction. 2nd ed. Hamilton: B.C. Decker Inc; 1999. p. 145-87.
26. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
28. Singh D. Small airway disease in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis 2017;80:317-24.
29. Foster WL Jr, Gimenez EI, Roubidoux MA, Sherrier RH, Shannon RH, Roggli VL, et al. The emphysemas: radiologic-pathologic correlations. Radiographics 1993;13:311-28.
31. Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, et al. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005;171:142-6.
32. Grydeland TB, Dirksen A, Coxson HO, Eagan TM, Thorsen E, Pillai SG, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med 2010;181:353-9.
33. Xie X, Dijkstra AE, Vonk JM, Oudkerk M, Vliegenthart R, Groen HJ. Chronic respiratory symptoms associated with airway wall thickening measured by thin-slice low-dose CT. AJR Am J Roentgenol 2014;203:W383-90.
34. Mair G, Maclay J, Miller JJ, McAllister D, Connell M, Murchison JT, et al. Airway dimensions in COPD: relationships with clinical variables. Respir Med 2010;104:1683-90.
37. Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995;152:267-76.
38. Kim V, Pechulis RM, Abuel-Haija M, Solomides CC, Gaughan JP, Criner GJ. Small airway pathology and bronchoreversibility in advanced emphysema. COPD 2010;7:93-101.
40. Karayama M, Inui N, Yasui H, Kono M, Hozumi H, Suzuki Y, et al. Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2019;14:1333-42.
42. Kirby M, Tanabe N, Tan WC, Zhou G, Obeidat M, Hague CJ, et al. Total airway count on computed tomography and the risk of chronic obstructive pulmonary disease progression: findings from a population-based study. Am J Respir Crit Care Med 2018;197:56-65.
43. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.
46. Johannessen A, Skorge TD, Bottai M, Grydeland TB, Nilsen RM, Coxson H, et al. Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med 2013;187:602-8.
47. Dournes G, Laurent F, Coste F, Dromer C, Blanchard E, Picard F, et al. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. Am J Respir Crit Care Med 2015;191:63-70.
49. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther 2014;4:416-29.
53. Aamli Gagnat A, Gjerdevik M, Gallefoss F, Coxson HO, Gulsvik A, Bakke P. Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort. Eur Respir J 2017;49:1601162.
55. Boushy SF. The use of expiratory forced flows for deter-mining response to bronchodilator therapy. Chest 1972;62:534-41.
57. Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 2006;100:1742-52.
59. Hoshino M, Ohtawa J. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology 2011;16:95-101.
60. Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD 2009;6:104-11.
61. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.